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Background: This study aimed to evaluate the relationship between the molecular phenotype of the primary
mammary tumor and its related lymph node metastasis in the dog to develop prognostic-predictive models and
targeted therapeutic options.
Results: Twenty mammary tumor samples and their lymph node metastases were selected and stained by
immunohistochemistry with anti-estrogen receptor (ER), -progesterone receptor (PR), -human epidermal growth
factor receptor 2 (c-erbB-2), -cytokeratin 5/6 (CK 5/6), -cytokeratin 14 (CK14), -cytokeratin 19 (CK 19) and -protein 63
(p63) antibodies. Four phenotypes (luminal A, luminal B, c-erbB2 overexpressing and basal-like) were diagnosed in
primary tumors and five (luminal A, luminal B, c-erbB-2 overexpressing, basal-like and normal-like) in the lymph
node metastases. Phenotypic concordance was found in 13 of the 20 cases (65%), and seven cases (35%) showed
discordance with different lymph node phenotypic profile from the primary tumor.
Conclusions: The phenotype of the primary tumor assumes a predictive-therapeutic role only in concordant cases,
meaning that both the primary tumor and its lymph node metastasis should be evaluated at the same time.
A treatment plan based only on the primary tumor phenotype could lead to therapeutic failures if the phenotype
of the lymph node metastasis differs from that of the primary tumor.
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Canine mammary tumors and human breast cancer are
heterogeneous diseases commonly occurring in female
dogs [1,2] and in women [3,4].
Traditionally, breast cancer has been classified by mor-
phological criteria in both human [5] and veterinary
[6,7] medicine. Recent veterinary attention has focused
on the protein expression profile [8,9] that seems to play
a crucial role in human medicine in determining the
clinical course, the use of chemoendocrine therapy [10],* Correspondence: giuseppe.sarli@unibo.it
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reproduction in any medium, provided the orand treatment effects [4]. Sorlie et al. [11] examined the
human expression profiles of 115 breast carcinomas iden-
tifying five subtypes: two hormone (oestrogen and/or pro-
gesterone) receptor-positive types (luminal-like A and
luminal B) and hormone receptor-negative types [human
epidermal growth factor receptor 2- overexpressing, basal-
like, and unclassified (“normal-like”)]. Further studies have
demonstrated the usefulness of immunohistochemistry in
spite of biomolecular investigations to detect the five
reported subtypes [12]. Based on classification of the
human gene expression profile, four main carcinoma sub-
types have been identified in canine species [8]: luminal A,
luminal B, c-erbB-2 overexpressing and basal-like.
Luminal-like phenotypes were characterized by ER and/ord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Individual data
N° AGE BREED OS – 730days*
1 9 mixed breed
2 12 German shepherd
3 7 Yorkshire terrier D (120)
4 6 English setter D (540)
5 10 Dobermann
6 13 mixed breed
7 11 Maremma shepherd A
8 13 mixed breed
9 11 mixed breed
10 11 mixed breed A
11 8 Dobermann D (600)
12 11 mixed breed
13 8 mixed breed D (320)
14 10 German shepherd A
15 11 mixed breed D (450)
16 14 mixed breed A
17 10 mixed breed A
18 10 English setter D (60)
19 10 mixed breed
20 11 poodle
*OS= Over-survival time after 730 days; D= dead; A= alive.
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c-erbB-2, and luminal B, positive for c-erbB-2 respectively.
Basal-like phenotypes were characterized by the absence
of ER, PR and the expression of cytokeratin 5/6 and/or
14 [8,9,13]. C-erbB-2 positivity in the basal-like tumors
characterizes the c-erbB-2 overexpressing group [14].
Sassi et al. [9] used a panel of antibodies to classify ca-
nine mammary carcinomas into three tumor subtypes
(luminal-like A and B and basal-like) out of the five
known in human medicine (no c-erbB-2 overexpressing
or normal-like types were found in this study) and out
of the four known in veterinary oncology (no normal-
like was also detected in the Gama et al. [8] work).
Recently, molecular characterization in human breast
cancer has also been applied to the metastasing lymph
nodes [15]. The metastatic process is in fact the most ur-
gent, important and difficult issue to approach in human
[16] and animal cancer medicine. The relationship be-
tween the primary tumor and the lymph node metastasis
from the same patient was studied by Wu et al. [15] to
determine if satellite tumors are uniform or divergent in
molecular properties and to provide new information of
diagnostic and therapeutic significance [16].
Recent publications emphasized several similarities
between human breast cancer and canine mammary
tumor, such as the relative age at onset, incidence, risk fac-
tors, biological behaviour, metastatic pattern, histopatho-
logical and molecular features, metastases-associated
expression profile [17], and response to therapy [18,19].
In human breast cancer therapies, endocrine therapy
is added to chemotherapy in hormone receptor–positive
subtypes; the c-erbB-2 overexpressing subtype is c-erbB-2
driven and appropriate for chemotherapy and c-erbB-2
targeted therapy such as trastuzumab. The basal-like
subtypes of breast cancer, which are not responsive to
endocrine therapy or trastuzumab, are entirely reliant
on chemotherapy [20,21]. In canine mammary tumors,
the therapeutic approach is mainly surgery, seldom
with adjuvant chemotherapy, but no standard thera-
peutic protocol is available [22,23]. Receptor evaluation
has been introduced to use an anti-estrogen therapy,
whose side-effects include endometritis in bitches with
ER negative tumors [24].
The aim of this study was to analyze the relationship
between the primary mammary tumor and its lymph
node metastasis based on immunohistochemical mo-
lecular characterization to develop the most specific




Specimens of mammary carcinomas from 20 female
dogs were collected from the database of the PathologyService of the Department of Veterinary Medical Science
of Bologna University and from the Department of Ani-
mal Pathology of Pisa University.
The 20 dogs comprised 11 mixed breed, two German
shepherd, one Yorkshire terrier, two English setter, two
Doberman, one Maremma shepherd and one poodle.
Dog ages ranged from six to 14 years with a mean age of
10.3 and a median of 10.5. Two-year follow-up survival
data were available for 11 out of the 20 animals with
invasive carcinomas included in the study. Overall sur-
vival time was defined as the time from the day of
diagnosis until the day of death or last follow-up. All
the latest data are summarized in Table 1.
Cases were selected based on both the primary mam-
mary neoplasia and histological grade II (grade II: inva-
sive carcinoma and metastases to regional lymph nodes)
according to Gilbertson et al. [25]. No cases displayed
systemic metastases. Samples were available as sections
stained with hematoxylin and eosin and obtained from
formalin-fixed and paraffin-embedded tissue block.
Histological diagnosis and immunohistochemistry
Histological diagnosis was made according to the WHO
classification system [6]. Seven consecutive 4μm-thick
sections were cut from the paraffin blocks containing
representative tumor samples and labeled by immuno-
histochemistry with the following antibodies: anti-ER,
Table 2 Primary antibodies, resources and dilutions used in immunohistochemistry
ANTIBODY (−ANTI) CLONE MANUFACTURER DILUTION
ER B-10 Abcam (Cambridge, UK) 1: 300
PR PR4-12 Oncogene TM (Boston, MA, USA) 1: 100
c-erbB-2 Polyclonal Dako (Glostrup, Denmark) 1: 250
Cytokeratins 5/6 D5/16B4 Zymed (South San Francisco, CA, USA) 1: 100
Cytokeratin 14 Ab-1 (LL002) NeoMarkers (Fremont, CA, USA) 1: 300
Cytokeratin 19 BA17 Dako (Glostrup, Denmark) 1: 50
p63 4A4 Dako (Glostrup, Denmark) 1: 50
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the primary antibodies are summarized in Table 2.
Sections were dewaxed in toluene and rehydrated.
Endogenous peroxidase was blocked by immersion in
H2O2 0.3% in methanol for 20 min. Sections were then
rinsed in Tris Buffer and antigen was retrieved with citrate
buffer (2.1 g citric acid monohydrate/liter distilled water),
pH 6.0 (except for CK 5/6 which use EDTA, pH 8.0), and
heating for two 5-min periods in a microwave oven at
750 W, followed by cooling at room temperature for
20 min. All antibodies were incubated with the tissue sec-
tions overnight at 4°C, and their binding was revealed by
a commercial streptavidin-biotin-peroxidase techniqueTable 3 Summary of immunohistochemical staining
SAMPLES ID PRIMARY MAMMARY TUMOR
ER* PR* c-erbB-2° CK 14* CK 5/6*
1 1 1 1 1 1
2 0 1 1 1 1
3 1 0 1 1 1
4 0 0 1 1 1
5 0 1 3 1 1
6 1 0 1 1 1
7 1 1 1 1 1
8 0 1 1 1 1
9 1 1 3 1 1
10 1 1 3 1 1
11 0 0 1 1 0
12 1 0 2 1 1
13 1 0 2 1 1
14 1 1 1 1 1
15 0 0 2 1 1
16 1 0 1 1 1
17 0 1 2 1 1
18 0 0 2 1 1
19 0 0 1 1 1
20 0 1 2 1 1
*ER, PR, CK5/6, CK14, p63: 0= no immunoreactivity; 1= immunoreactivity. °c-erbB-2:
membranous immunostaining; 3= >90% complete membranous cell positivity.(LSAB Kit, Dako, Amsterdam, The Netherlands). Diami-
nobenzidine (0.05% for 10 min at room temperature) was
used as chromogen. Slides were counterstained with
Papanicolaou's hematoxylin.
As a negative control, the primary antibody was
replaced with an irrelevant, isotype-matched antibody to
control for non-specific binding of the secondary anti-
body. As positive controls to assess the cross-reactivity
with canine tissues and the specificity of the immunohis-
tochemical stain, sections of normal canine uterus (for
anti-ER and -PR antibodies), canine skin (for anti-CK5/
6, -CK14, -CK19 and -p63 antibodies) were used follow-
ing the same protocols. A human poorly differentiatedLYMPH NODE METASTASIS
p63* ER* PR* c-erbB-2° CK 14* CK 5/6* p63*
0 0 1 1 1 1 0
0 0 1 1 1 1 0
1 0 0 0 0 0 0
0 0 0 1 1 1 0
1 0 1 3 1 1 0
1 0 0 1 1 1 1
1 1 1 0 1 1 0
0 0 0 1 1 1 0
1 0 0 3 1 1 0
1 1 1 3 1 1 0
0 0 0 1 1 0 0
1 0 0 1 1 1 0
1 0 0 1 0 0 0
0 1 0 1 1 1 0
0 0 0 3 1 1 0
0 1 0 1 0 1 0
0 0 1 2 1 1 0
1 0 0 2 0 0 0
0 0 0 1 1 1 0
1 0 0 2 1 1 1
0= no immunoreactivity; 1= <10% positive cells; 2= 10 to 90% complete












1 Luminal A Luminal A Concordance
2 Luminal A Luminal A Concordance
3 Luminal A Normal-like Discordance
4 Basal-like Basal-like Concordance
5 Luminal B Luminal B Concordance
6 Luminal A Basal-like Discordance
7 Luminal A Luminal A Concordance
8 Luminal A Basal-like Discordance
9 Luminal B c-erbB-2
overexpressing
Discordance
10 Luminal B Luminal B Concordance
11 Basal-like Basal-like Concordance
12 Luminal B Basal-like Discordance
13 Luminal B Normal-like Discordance






16 Luminal A Luminal A Concordance






19 Basal-like Basal-like Concordance
20 Luminal B c-erbB-2
overexpressing
Discordance
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P. Viacava, Department of Oncology, University of Pisa,
Italy) known to react with c-erbB-2 antibody was used
as positive control.
The staining result was classified semi-quantitatively
with a dichotomous evaluation: positive or negative. The
sample was considered positive:
 when presenting cytoplasmic stain in more than 1%
of the invasive tumor cells for anti-CK-19, CK-5/6
and anti-CK14 antibodies [26];
 when presenting complete membranous stain in
more than 10% of tumor cells for anti- c-erbB-2
antibody according to the Hercept-test [27];
 when presenting nuclear stain in more than 5% of
tumor cells for anti-ER and anti-PR antibodies [28];
 when presenting nuclear stain in more than 10%
of tumor cells for anti-p63 antibody [29].
Molecular taxonomy
The application of the panel allowed cases to be grouped
into five molecular subtypes according to an algorithm
by Sassi et al. [9] modified as follows:
 Luminal-A: ER+ and/or PR+, c-erbB-2–, regardless
of CK5/6, CK14, p63 staining.
 Luminal-B: ER+ and/or PR+, c-erbB-2+, regardless
of CK5/6, CK14, p63 staining.
 c-erbB-2 overexpressing: ER–, PR–, c-erbB-2+
regardless of CK5/6, CK14, p63 staining.
 Basal-like: ER–, PR–, c-erbB-2–, CK5/6+ and/or
CK14+ and/or p63+.
 Normal-like: Negative to all markers.
Results
Diagnosis
Eight of the 20 primary tumors were classified as simple
tubulopapillary carcinomas, eight as solid carcinomas,
two as complex carcinomas and two as anaplastic
carcinomas.
Immunohistochemistry and molecular phenotypes
Immunohistochemistry for ER, PR, c-erbB-2, CK5/6,
CK14, p63 in the primary tumor and in the respective
lymph node metastasis is summarized in Table 3. In
each case the epithelial origin of cancer was confirmed
by CK19 staining. Based on the applied algorithm, mo-
lecular phenotypes were obtained in the primary mam-
mary tumors and in their lymph node metastases
(Table 4). Four phenotypes (luminal A (Figure 1A-B, line
1-2-3), luminal B (Figure 2A-B, line 1-2-3-4), c-erbB-2
overexpressing (Figure 3A-B), basal-like (Figure 4A-B-C))
were diagnosed in primary tumors (eight (40%), seven
(35%), two (10%), three (15%) respectively) and five(luminal A (Figure 1C-D-E, line 1), luminal B (Figure 2C-
D-E, line 1), c-erbB-2 overexpressing (Figure 2C-D-E, line
2 and Figure 3C-D-E), basal-like (Figure 2C-D-E, line 3 and
Figure 4C-D-E), normal-like (Figure 1C-D-E, line 3 and line
4 of Figure 2C-D-E)) in the lymph node metastases (five
(25%), three (15%), four (20%), six (30%), two (10%)
respectively).
Relationship between molecular phenotype in the
primary mammary tumor and its related lymph node
metastasis
Phenotypic concordance was found in 13 of the 20 cases
(65%) (five luminal A (Figure 1, line 1), three luminal B
(Figure 2, line 1), two c-erbB-2 overexpressing (Figure 3)
and three basal-like (Figure 4)). Seven cases (35%)
showed discordance with lymph node phenotypic profile
differing from the primary tumor (two luminal A be-
came basal-like (Figure 1, line 2), one luminal A became
normal-like (Figure 1, line 3), two luminal B became
c-erbB-2 overexpressing (Figure 2, line 2), one luminal
Figure 1 Luminal A phenotype: concordant and discordant cases. Line 1: Luminal A concordant case with ER+ and c-erbB-2– (1A, 1B) in the
primary tumor and ER+, cerbB-2–, CK14– (1C, 1D, 1E) in the lymph node metastases. Line 2: Discordant case with luminal A phenotype PR+,
c-erbB-2– (2A, 2B) in the mammary tumor and progression to basal-like phenotype PR–, c-erbB-2–, CK14+ (2C, 2D, 2E) in the respective nodal
metastasis. Line 3: Discordant case presenting in the primary mammary carcinoma luminal A phenotype ER+, c-erbB-2– (3A, 3B) and normal-like
phenotype ER–, cerbB-2–, CK5/6– (200x) (3C, 3D, 3E) in the lymph node. 400x.
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B became normal-like (Figure 2, line 4)) (Table 3).
C-erbB-2 overexpressing and basal-like primary tumors
were 100% concordant with the molecular phenotype of
the respective lymph node metastases (Figure 3 and
Figure 4). Luminal A and luminal B were concordant
in 65.2% and 42.9% respectively of primary tumors
for the same comparison.
Histological diagnosis in primary mammary tumor
compared to molecular phenotypes and to
concordance/discordance
In the primary tumor the luminal A phenotype displayed
a different histological tumor pattern, i.e. simple tubulopa-
pillary (one case) (Figure 1A-B, line 1), solid (six cases)
(Figure 1A-B, line 2), anaplastic (one case) (Figure 1A-B,
line 3). Luminal B phenotype displayed a different histo-
logical tumor pattern, i.e. simple tubulopapillary (four
cases) (Figure 2A-B, line 1 and 4), solid (two cases)
(Figure 2A-B, line 2) and complex (one case) (Figure 2A-B,
line 3). The c-erbB-2 overexpressing phenotype showed
two patterns, i.e. tubulopapillary (one case), and ana-
plastic (one case) (Figure 3A-B). The basal-like pheno-
type displayed different histological tumor patterns, i.e.
simple tubulopapillary (two cases) (Figure 4A-B-C) and
complex (one case). No association was found between
histological diagnosis and phenotype in the primary
tumor (Pearson Chi-square, P=0.065; for statistics only
the tubulopapillary and the solid carcinomas wereconsidered because the other two types had only one
case for phenotype).
Six cases with tubulopapillary pattern displayed con-
cordance between the primary tumor and its related
lymph node metastasis whereas the other two cases
showed discordance. In the solid pattern concordance
was found in five cases and discordance in three. In the
anaplastic and complex patterns both concordance and
discordance were present with one case for each type.
Comparing the four histological patterns, no differences
in the percentages of concordance/discordance were
evident (Pearson Chi square P=0.857, for statistics only
the tubulopapillary and the solid carcinomas were con-
sidered because the other two types had only one case
for each phenotype).Influence of the molecular phenotype and
concordance/discordance on dog’s survival rate
Table 1 reports the survival data of the 11 animals. Few
data are available to group the subjects according to
molecular phenotypes and concordance/discordance to
perform survival analysis even though it appears that
all five animals alive at 24 months post-surgery were
concordant luminal A or luminal B cases. The other
six dead animals bore primary tumor/lymph node con-
cordant (2 basal-like and 2 c-erbB-2 overexpressing) or
discordant (1 luminal A/normal like; 1 luminal B/nor-
mal-like) cases in which less differentiated molecular
Figure 2 Luminal B phenotype: concordant and discordant cases. Line 1: Luminal B concordant case with PR+ and c-erbB-2+ (1A, 1B) in
theprimary neoplasia and PR+, cerbB-2+, CK14+ (1C, 1D, 1E) in the lymph node metastases. Line 2: Discordant case showing luminal B phenotype
PR+, c-erbB-2+ (2A, 2B) in the primary tumor becoming c-erbB-2 overexpressing phenotype in the lymph node PR–, c-erbB-2+, CK5/6+ (2C, 2D,
2E). Line 3: Discordant case with luminal B phenotype ER+, c-erbB-2+ (3A, 3B) in the mammary tumor and progression to basal-like phenotype
ER–, c-erbB-2–, CK 14+ (3D, 3E, 3F) in the respective nodal metastasis. Line 4: Discordant case presenting in the primary mammary carcinoma
luminal A phenotype ER+, c-erbB-2– (4A, 4B) and normal-like phenotype PR–, cerbB-2–, p63– (4D, 4E, 4F) in the lymph node. 400x.
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node compared to the live animals.
Discussion
Canine mammary carcinomas can become fatal due to
the development of distant metastases. One of the most
important prognostic factors in the diagnosis is the ac-
knowledgment of metastases to the regional lymph node
that represents an early step in metastatic spread [30].
Klopfleisch et al. [17] and Lu et al. [31] demonstrated
that metastatic spread of canine mammary tumor to the
lymph nodes is associated with a gene expression profile
of increased cell cycle progression, altered cellFigure 3 C-erbB-2 overexpressing phenotype: concordant case. PR–, c
(2C, 2D, 2E) in the respective lymph node metastasis. 400x.differentiation and decreased growth factor signaling.
Metastasis development is a complex process involving
invasion, intravasation, survival in the bloodstream, ex-
travasation and homing and proliferation at the site of
metastasis [32]. Although some phenotypes showed
greater aggressiveness and metastatic capability, only a
selected subpopulation was able to metastatize in the
multiple and heterogeneous tumor cell population. In
this case the phenotype may have been transient and
these selected cells have had an intrinsic program to
transition to a phenotype enhancing their ability for het-
erotypic interaction and survival proliferation in distant
organs [32] as Darwinian clonal evolution. Conversely,-erbB-2+ (1A, 1B) in mammary tumor and PR–, c-erbB-2+, p63– (200x)
Figure 4 Basal-like phenotype: concordant case. ER–, c-erbB-2–, CK5/6+ (1A, 1B, 1C) in mammary neoplasia and PR–, c-erbB-2–, CK 14+
(2C, 2D, 2E) in the lymph node metastasis. 400x.
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chastic event, the primary tumor cells having equal
metastatic capability, characterized by a phenotypic
overlap between the primary tumor and its metastases
[33,34]. Thus the identification of molecular phenotypes
in primary tumors and metastases can provide predictive
information on the most likely metastatic profile, not
the condition in the primary tumor.
Sassi et al. [9] identified three phenotypes out of the
four detected by Gama et al. [8], demonstrating that
basal-like subtypes were associated with a better out-
come than luminal A and luminal B tumors, in contrast
with the findings of Gama et al. [8]. The prognostic role
of c-erbB-2 overexpression remains controversial des-
pite what is known in human medicine. According to a
study by Hsu et al. [35], the relationship between the
clinical course and protein expression of c-erbB-2 in
dogs with malignant mammary neoplasia indicated a
greater survival rate in tumors overexpressing c-erbB-2
compared to those having non-overexpressed levels of
antigen. Certainly, c-erbB-2 plays an important role in
carcinogenesis, but does not seem to be directly corre-
lated with progression to malignancy [35]. In the
present investigation it seems that luminal A or B con-
cordance should be considered a positive prognostic
factor, whereas concordance for the other molecular
types or discordance should not, even if these results
await confirmation in a larger number of cases and
proper statistical analysis.
This study revealed four out of the five protein expres-
sion phenotypes of breast cancer in primary tumors
(20 cases): luminal A (40%), luminal B (35%), c-erbB-2
overexpressing (10%) and basal-like (15%). The preva-
lence of luminal phenotypes (75%) over the others
(25%) is in accordance with findings both in human
[11,36,37] and veterinary [8,9] medicine.
Based on the present study and in agreement with
Brunetti et al. [38], labeling for CK and p63 would only
appear necessary when a tumor is negative for ER, PR
and c-erbB-2.
With regard to luminal A and B phenotypes, the ex-
pression profiles of ER and PR are essential to decide on
the application of endocrine therapy [39] in breast can-
cer and canine mammary neoplasia, and also seem toplay a minor role in predicting tumor biological behav-
iour [40,41]. Wu et al.’s study [15] in breast cancer con-
firmed the observation that ER and/or PR could be lost
when carcinomas metastasizes, thereby resisting endo-
crine therapy. The present study shows almost overlap-
ping results, losing hormone receptors by moving from
luminal A to basal-like (2 cases) and/or to normal-like
(1 case) phenotypes and from luminal B to c-erbB-2
overexpressing (2 case) and/or to basal-like (1 case),
and/or to normal-like (1 case), confirming that the gene
expression profile in canine mammary tumors may
prove a helpful tool in clinical practice. Chang et al. [42]
indicated that the ER or PR expression in dogs was asso-
ciated with tumor size, clinical stage, and lymph node
metastasis or distant metastases. Dogs with malignant
mammary neoplasia and expression of both ER and PR
had a longer survival rate than dogs with malignant
mammary tumors that were ER positive but PR negative.
This latest information on PR suggested that the recep-
tor was a better outcome predictor than ER status alone
and that its positive or negative expression could serve
as a prognostic factor, especially in dogs with malignant
neoplasia with ER expressed [42]. The present results
disclosed a high prevalence of hormone receptor expres-
sion in the primary tumor, whose positivity was ensured
by reactivity to least one of the two markers (ER and/or
PR) (Table 3). The latest results indicate that there are
grounds for the use of anti-hormone therapy in dogs,
administering molecules other than those hitherto used
in veterinary medicine (tamoxifen) as their side-effects
are already well-known [24]. A similar analysis in lymph
node showed a net loss of hormone receptor expression,
namely ER. ER loss is a known adverse prognostic factor
[42], and therefore its lack of expression in metastases is
indicative. In this study, only five out of the 20 cases
showed positivity to both ER and PR in the primary
tumor, with persistent positivity in the lymph node me-
tastasis in only two cases. The remaining three cases
showed loss of one or both hormone receptor staining
in the lymph node metastasis: loss of ER (case n° 1), loss
of PR (case n° 14) and concomitant loss of ER and PR
(case n° 9). According to the literature, these cases
should have a poor prognosis, justified by our pheno-
types, but with maintained luminality in the first two
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meaning a even worse evolution by the complete loss of
ER and PR.
Interestingly, cases n° 3 and n° 13 (Table 3) in which
in lymph node metastasis occurred, lost all the markers
expressed in the primary tumor, likely due to the selec-
tion of a significantly aggressive cell subpopulation. The
normal-like or multiple markers negative (MMN) sub-
type tumors have been shown to be negative for basal
markers, such as CK5/6 and CK14 in our cases, and
negative for other molecular markers. The majority of
normal-like subtype tumors express CK8/18, CK19 (used
in this study), with an absence of CK5/6 suggesting that
these cells were most probably derived from a luminal
gland cell [43]. The normal-like subtype is also included
in the triple negative breast cancer group (TNBC) char-
acterized by an aggressive clinical course, poor survival
rate and, unlike the overexpressing hormone receptors
or c-erbB-2-overexpressing tumors, is not amenable to
hormone therapy or c-erbB-2-directed agents [44]. Al-
though no correlation has been found between histo-
logical type and phenotype, the normal-like cases
represent an exception.
The present study identified five phenotypes in the
lymph node metastases: luminal A (25%), luminal B
(15%), c-erbB-2 overexpressing (20%), basal-like (30%)
and normal-like (10%). The novel aspect of this study is
the evaluation of the lymph node metastasis phenotypes
and their correlation with the primary tumor, never hith-
erto applied to canine species. The relationship between
the primary tumor and metastatic phenotype is defined
by a concordance in 65% of cases and a discordance in
the remaining 35%, suggesting the two main metastatic
capability theories coexist. All seven discordant cases
showed a progressive behavior, according to the prog-
nostic value of molecular phenotypes reported by Gama
et al. [8], suggesting phenotypic evolution with a worse
prognosis from the primary tumor to lymph node
metastasis.Conclusions
Molecular phenotype classification is a new model urgently
needed in veterinary medicine. This model will fill current
gaps regarding prognosis and a targeted therapeutic ap-
proach, since the primary tumor phenotype does not al-
ways overlap with that of its metastasis. According to the
present findings, the primary tumor phenotype assumes a
predictive-therapeutic role only in concordant cases, mean-
ing that there should be a concomitant evaluation of both
the primary tumor and its lymph node metastasis. Treat-
ment planning based only on the primary tumor phenotype
can lead to therapeutic failures if the lymph node meta-
static phenotype differs from that of the primary tumor.Competing interests
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